ARG098: A New Treatment for Rheumatoid Arthritis
Author Information
Author(s): Odani-Kawabata Noriko, Takai-Imamura Miwa, Katsuta Osamu, Nakamura Hiroshi, Nishioka Kusuki, Funahashi Keiko, Matsubara Tsukasa, Sasano Minoru, Aono Hiroyuki
Primary Institution: Santen Pharmaceutical Co., Ltd.
Hypothesis
Can the anti-Fas antibody ARG098 effectively reduce synovial hyperplasia and prevent cartilage destruction in rheumatoid arthritis?
Conclusion
ARG098 treatment suppressed RA synovial hyperplasia and prevented cartilage destruction in vivo.
Supporting Evidence
- ARG098 induced apoptosis in RA synoviocytes and infiltrating lymphocytes in a dose-dependent manner.
- ARG098 treatment significantly decreased the number of infiltrating lymphocytes in the RA synovium.
- ARG098 did not affect the viability of peripheral blood mononuclear cells from RA patients.
- Histopathological analysis showed reduced synovial hyperplasia and cartilage destruction in ARG098-treated tissues.
Takeaway
ARG098 is a new medicine that helps people with rheumatoid arthritis by making the bad cells in their joints go away, which helps protect their joints.
Methodology
The study used flow cytometry, cell viability assays, and a SCID-HuRAg mouse model to evaluate the effects of ARG098 on RA synoviocytes and infiltrating lymphocytes.
Potential Biases
Potential bias due to the involvement of authors from Santen Pharmaceutical Co., Ltd., the company developing ARG098.
Limitations
The study did not assess the long-term effects of ARG098 or its potential adverse effects on non-target cells in humans.
Participant Demographics
RA patients from whom synovial tissues and cells were obtained.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website